Entity

Time filter

Source Type


Qu L.-S.,Nantong University | Chen H.,Nantong University | Kuai X.-L.,Nantong University | Xu Z.-F.,Nantong University | And 2 more authors.
Hepatology Research | Year: 2012

Aim: The role of interferon (IFN) therapy on prevention of hepatocellular carcinoma (HCC) in patients with hepatitis C virus (HCV)-related cirrhosis remains controversial. This meta-analysis aimed to determine whether IFN therapy reduced the incidence of HCC in HCV-related cirrhotic patients. Methods: We performed a meta-analysis including eight randomized controlled trials (RCT) (a total of 1505 patients) to assess the effect of IFN therapy on prevention of HCC in patients with HCV-related cirrhosis. The pooled odds ratios (OR) were calculated using a random or fixed effects model. Results: Our results showed that IFN therapy significantly decreased the overall HCC incidence in HCV-related cirrhotic patients (OR, 0.29; 95% confidence interval [CI], 0.10-0.80; P=0.02). HCC risk in patients who failed to achieve sustained virological response (SVR) in the initial IFN-based treatment was also reduced by maintenance IFN therapy (OR, 0.54; 95% CI, 0.32-0.90; P=0.02). Subgroup analysis indicated that IFN therapy decreased HCC incidence in HCV-related cirrhotic patients during long-term follow up (>48months) evidently (OR, 0.25; 95% CI, 0.09-0.67; P=0.006). However, subgroup analysis of four RCT with short-term follow up (≤48months) did not demonstrate the significant difference in HCC incidence between IFN-treated cirrhotic patients and controls (OR, 0.78; 95% CI, 0.39-1.55; P=0.48). Conclusion: The present study suggested that IFN therapy could efficiently reduce HCC development in patients with HCV-related cirrhosis; this effect was more evident in the subgroup of patients with long-term follow up (>48months). Patients who received maintenance IFN therapy had a lower risk of HCC than controls. © 2012 The Japan Society of Hepatology. Source


Wang H.,Shanghai Pudong New Area Gongli Hospital | Jiang M.,Shanghai Pudong New Area Gongli Hospital | Zhu H.,Shanghai Pudong New Area Gongli Hospital | Chen Q.,Shanghai Xuhui Central Hospital | And 4 more authors.
Molecular Biology Reports | Year: 2013

The proteasome system is a proteolytic pathway that regulates the expression of genes involved in inflammation. Recently, an association of a functional sequence variation, -8C/G, in the human proteasome subunit a type 6 gene (PSMA6) with the susceptibility to coronary artery disease (CAD) was reported. After that, several validation studies have been conducted among various ethnic populations, but the results have been inconsistent. To investigate this inconsistency and derive a more precise estimation of the relationship, a meta-analysis of 15,991 cases and 16,784 controls from 10 case-control studies was performed. Potential sources of heterogeneity including ethnicity, sample size and HWE status of study were also assessed. In a combined analysis, the summary per-allele OR for CAD of the -8C/G polymorphism was 1.09 (95 % CI: 1.02-1.16; P = 0.006). In the subgroup analysis by ethnicity, significantly increased risks were found in East Asians for the polymorphism; while no significant associations were found among Caucasians and other ethnic population in all genetic models. When restricted to studies concerning myocardial infarction patients, significant associations were detected in all genetic models. Furthermore, significant difference of PSMA6 mRNA expression was found between genotypes. In conclusion, this meta-analysis suggests that G allele of PSMA6-8C/G polymorphism is a risk factor associated with increased CAD susceptibility, but these associations vary in different ethnic populations. © 2012 Springer Science+Business Media Dordrecht. Source


Zhang Y.W.,Shanghai Xuhui Central Hospital
Orthopaedic surgery | Year: 2012

Using 64-slice spiral CT to reconstruct virtual knee joints of adults, we measured the gradient of proximal tibia-fibular joint and compared this result with bare joint measurement. We then discuss the accuracy of these measurements using a 64-slice spiral CT. Two hundred healthy adults were selected, including 100 males and 100 females, aged from 18 to 90 years. The gradient of the longitudinal axis of the fibula and the articular surface, and the angle of horizon of the proximal tibia-fibular articular surface and the horizontal line were measured by using a 64-slice spiral CT scan. The angle between the longitudinal axis of the fibula and the articular surface (angle A) was 56.80° ± 6.59°, both the left and the right fibula showed no significant difference (t = 0.308, P = 0.758). The angle between horizontal line and the articular surface (angle B) was 32.80° ± 6.49°. The regression or correlation analysis findings showed that there is a negative relationship (r = -0.952, P = 0.000), and there is significant difference (t = 51.87, P < 0.01) between the angle A and the angle B. The measurement value of using 64-slice spiral CT to reconstruct the slope of proximal tibia-fibular joints has no difference compared to the measurement value of the slope of bare proximal tibia-fibular joints. It is a precise, convenient method and is easy to apply for clinical study. © 2012 Tianjin Hospital and Blackwell Publishing Asia Pty Ltd. Source


Zhang Z.,Shanghai Xuhui Central Hospital
American Journal of the Medical Sciences | Year: 2012

In this study, the authors explored the therapeutic effect of glycyrrhizin (GL) on Coxsackievirus B3 (CVB3)-induced myocarditis and its possible mechanisms involved. The results of this study showed that GL exhibited a profound amelioration of CVB3-induced myocarditis, as evidenced by improved weight loss profile, less increased serological levels of cardiac enzymes, less myocardial inflammation and increased survival rate. Further study showed that this effect was not due to the viral clearance but ascribed to weakened proinflamma-tory responses, as evidenced by significantly reduced expression of proinflammatory cytokines, including tumor necrosis factor-α, interleukin-1β and interleukin-6. Moreover, the authors demonstrated that GL administration inhibited CVB3-induced nuclear factor-κB activity efficiently by blocking the degradation of nuclear factor-κB inhibitor IκBκ. These data suggest that GL can effectively attenuate the severity of CVB3-induced myocarditis and may present as a new therapeutic approach for the treatment of viral myocarditis. © 2012 Southern Society for Clinical Investigation. Source


Qu L.-S.,Nantong University | Liu J.-X.,Nantong University | Kuai X.-L.,Nantong University | Xu Z.-F.,Nantong University | And 2 more authors.
Hepatology Research | Year: 2014

Aim: The impact of viral status on recurrence of hepatitis B-related hepatocellular carcinoma (HCC) after curative therapy remains controversial. This meta-analysis aimed to determine whether the presence of viral load, genotype, specific mutation and antiviral therapy influenced HCC recurrence after curative therapy. Methods: We performed a meta-analysis including 20 studies to assess the effect of viral status and antiviral therapy with nucleoside analog on recurrence of HCC after curative therapy. The pooled odds ratios (OR) were calculated using a random or fixed effects model. PUBMED, MEDLINE, EMBASE and the Cochrane Database were searched for articles published from 1990 to December 2012. Results: Our results showed that the presence of high viral load significantly increased overall HCC recurrence risk after curative therapy. Pooled data from four studies on the recurrence rate among patients with genotype C infection compared with genotype B showed an increased risk of recurrence. Basal core promoter (BCP) mutation was associated with a significant risk in the recurrence of HCC. The pooled estimate of treatment effect was significantly in favor of a preventive effectiveness of antiviral therapy. Conclusion: The present study suggested that HCC patients with high viral load, genotype C and BCP mutation had a significantly higher risk of recurrence. Antiviral therapy has potential beneficial effects after the curative treatment of HCC in terms of tumor recurrence. © 2013 The Japan Society of Hepatology. Source

Discover hidden collaborations